Who Owns Olema Oncology Company?

Who Owns Olema Oncology?

Olema Oncology, a biopharmaceutical company focused on women's cancers, had its IPO in November 2020. Founded in 2006/2007, it aims to develop novel therapies for cancer treatment.

As of July 25, 2025, Olema Pharmaceuticals has a market capitalization of approximately $318.84 million, trading on the Nasdaq under OLMA. Its lead candidate, palazestrant, is in Phase 3 trials for ER+ breast cancer.

Understanding Olema Oncology's ownership is key to grasping its strategic direction and governance. The company's journey from its founding to its public listing has reshaped its stakeholder base.

The ownership structure of Olema Oncology has evolved significantly since its inception. Early investors and founders laid the groundwork, but the company's public offering in November 2020 marked a substantial shift. This transition brought in a broader base of shareholders, including institutional investors and the public market. The development of its lead candidate, palazestrant, a key component in its Olema Oncology BCG Matrix, has been a significant factor influencing investor interest and, consequently, ownership patterns.

Olema Oncology was established in 2007, with some records suggesting a founding year of 2006. Initially known as Olema Pharmaceuticals, Inc., the company's early growth was significantly supported by substantial venture capital infusions. While precise initial ownership percentages are not publicly detailed, the company's trajectory was shaped by its early financial backing.

Founder's Vision

Peter Kushner founded Olema Oncology in 2007, aiming to develop targeted therapies for women's cancers. The company's early development was crucial for advancing its lead product candidate.

Early Funding Rounds

Olema Oncology secured significant venture capital, raising a total of $139 million across multiple funding rounds before its initial public offering. This funding was vital for clinical trial progression.

Series B Financing

In July 2020, Olema Oncology successfully closed an oversubscribed Series B financing round, raising $54 million. This capital injection was instrumental in the company's ongoing research and development efforts.

Series C Leadership

The company's Series C financing round in October 2020 brought in $85 million, led by Vivo Capital. This round saw participation from prominent investors, underscoring confidence in Olema's mission.

Key Early Investors

A consortium of notable institutional investors, including BVF Partners and Logos Capital, participated in the Series C round. Their involvement highlights early stakeholder belief in Olema Oncology's potential.

Venture Capital Backing

Olema Oncology's early development was significantly fueled by venture capital. This financial backing was crucial for advancing its lead product candidate, OP-1250, into clinical trials.

The early ownership structure of Olema Oncology was heavily influenced by its significant venture capital backing, with prominent firms like BVF Partners, Logos Capital, and Vivo Capital playing key roles. These investors participated in substantial funding rounds, including an $85 million Series C in October 2020, which was critical for advancing the company's lead product candidate. This early financial support from major healthcare investors demonstrated a strong conviction in Olema's strategic direction and its Growth Strategy of Olema Oncology.

Founding and Initial Development

Olema Oncology, initially named Olema Pharmaceuticals, Inc., was founded by Peter Kushner in 2007. The company's early years were focused on building a strong foundation for its therapeutic development pipeline.

• Founder: Peter Kushner
• Original Company Name: Olema Pharmaceuticals, Inc.
• Founding Year: 2007 (some sources indicate 2006)
• Primary Focus: Targeted therapies for women's cancers

Complete Olema Oncology Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Olema Oncology transitioned to a public entity through its Initial Public Offering (IPO) on November 19, 2020, on the Nasdaq Global Select Market under the ticker 'OLMA.' This event marked a significant shift in its ownership structure, making it accessible to a broader range of investors and establishing its current Olema Oncology ownership profile.

The company's journey as a public entity began with its IPO, which offered 11,000,000 common shares at $19.00 per share, raising $209.0 million in gross proceeds. An additional 1,650,000 shares were purchased through the underwriters' option, boosting the total gross proceeds to approximately $240.4 million. As of July 25, 2025, Olema Pharmaceuticals has a market capitalization of $318.84 million, with 68,421,277 outstanding shares, reflecting the current Olema Oncology stakeholders.

Key Institutional Investors

Significant institutional investors continue to play a crucial role in Olema Oncology's ownership structure. These entities demonstrate sustained confidence in the company's strategic direction and pipeline development.

• Adage Capital Partners LP
• Bain Capital Life Sciences
• BVF Partners L.P.
• Driehaus Capital Management
• Janus Henderson Investors
• Paradigm BioCapital Advisors
• Wellington Management
• Woodline Partners LP
• A large investment manager

In December 2024, Olema Oncology secured $250 million through an equity private placement. This funding round saw participation from both new and existing institutional and accredited investors. Notable participants included Adage Capital Partners LP, Bain Capital Life Sciences, BVF Partners L.P., Driehaus Capital Management, Janus Henderson Investors, Paradigm BioCapital Advisors, Wellington Management, and Woodline Partners LP, alongside a major investment manager. These investments underscore the ongoing support from key financial backers and highlight the Olema Oncology investors' commitment. For detailed insights into the Olema Oncology company structure and shareholding patterns, investors can refer to the company's SEC filings, such as its annual (10-K) and quarterly (10-Q) reports, which provide comprehensive financial performance data and ownership breakdowns. Understanding these filings is essential for a complete picture of the Competitors Landscape of Olema Oncology.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The Board of Directors at Olema Oncology is instrumental in guiding the company's strategic direction and corporate governance. Sean P. Bohen, M.D., Ph.D., serves as both President and Chief Executive Officer, and holds a position on the board. He assumed leadership in September 2020.

While specific details regarding major shareholder representation on the board or the existence of dual-class shares are not readily available in public summaries, the board's composition typically aims for a balance between executive leadership, representatives from significant investors, and independent directors. For precise information on board composition and voting structures, consulting the company's investor relations website or SEC filings is recommended. Olema Oncology generally operates under the standard one-share-one-vote principle common for Nasdaq-listed companies, unless its charter documents specify otherwise. The absence of widely reported proxy contests suggests a stable governance framework.

Olema Oncology's Governance Structure

The company's leadership team is responsible for day-to-day operations and strategic execution. Understanding the Marketing Strategy of Olema Oncology can provide further insight into their operational focus.

• Board of Directors oversees strategic decisions.
• Executive team manages operational and financial aspects.
• Corporate governance adheres to standard public company practices.
• Investor relations provide detailed company information.

Olema Oncology Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Olema Oncology has experienced significant shifts in its ownership landscape over the past three to five years, marked by substantial capital raises and evolving investor confidence. A key event was the $250 million equity private placement in December 2024, which attracted both new and existing institutional investors, reinforcing the company's financial foundation and indicating strong backing for its development programs.

Financially, Olema Oncology reported substantial liquidity, with $434.1 million in cash, cash equivalents, and marketable securities as of December 31, 2024, and $392.7 million as of March 31, 2025. The company's net loss for 2024 was $129.5 million, largely attributed to increased investments in late-stage clinical trials for palazestrant and the progression of OP-3136. This financial activity highlights a strategic emphasis on research and development, a common characteristic of clinical-stage biopharmaceutical entities. The leadership, with Sean P. Bohen serving as President and CEO since September 2020, has remained consistent. The company has not engaged in significant share buybacks or secondary offerings outside of the December 2024 private placement. The ownership structure of Olema Oncology reflects a transition from early venture capital support to a more diversified institutional investor base following its initial public offering, a trajectory typical for biotechnology firms. Future changes in Olema Oncology ownership trends will likely be influenced by the outcomes of its clinical trials, potential strategic collaborations, and overall market performance, with a continued focus on advancing palazestrant through Phase 3 trials and initiating the OPERA-02 trial in 2025. Understanding the Brief History of Olema Oncology provides context to these ownership shifts.

Olema Oncology Stakeholder Profile

Olema Oncology's stakeholder base has expanded significantly with the recent private placement. The company now benefits from the backing of major institutional investors, indicating a robust level of confidence in its clinical pipeline and strategic direction.

Capitalization and Financial Health

As of early 2025, Olema Oncology maintained strong liquidity with hundreds of millions in cash reserves. This financial strength is crucial for funding its extensive clinical trial programs and advancing its lead drug candidates.

Leadership and Strategic Focus

The consistent leadership since 2020 provides stability as the company navigates its development path. The primary focus remains on the successful progression of palazestrant through critical clinical phases.

Ownership Evolution Trends

Olema Oncology's ownership structure has evolved from early-stage venture capital to a broader institutional investor base. This shift is a natural progression for a company advancing through clinical development and preparing for potential commercialization.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE